Full Text

Turn on search term navigation

© 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Objectives

Following infection with SARS‐CoV‐2, virus‐specific antibodies are generated, which can both neutralise virions and clear infection via Fc effector functions. The importance of IgG antibodies for protection and control of SARS‐CoV‐2 has been extensively reported. By comparison, other antibody isotypes including IgA have been poorly characterised.

Methods

Here, we characterised plasma IgA from 41 early convalescent COVID‐19 subjects for neutralisation and Fc effector functions.

Results

Convalescent plasma IgA from > 60% of the cohort had the capacity to inhibit the interaction between wild‐type RBD and ACE2. Furthermore, a third of the cohort induced stronger IgA‐mediated ACE2 inhibition than matched IgG when tested at equivalent concentrations. Plasma IgA and IgG from this cohort broadly recognised similar RBD epitopes and had similar capacities to inhibit ACE2 from binding to 22 of the 23 prevalent RBD mutations assessed. However, plasma IgA was largely incapable of mediating antibody‐dependent phagocytosis in comparison with plasma IgG.

Conclusion

Overall, convalescent plasma IgA contributed to the neutralising antibody response of wild‐type SARS‐CoV‐2 RBD and various RBD mutations. However, this response displayed large heterogeneity and was less potent than IgG.

Details

Title
Heterologous SARS‐CoV‐2 IgA neutralising antibody responses in convalescent plasma
Author
Davis, Samantha K 1 ; Selva, Kevin John 1 ; Lopez, Ester 1 ; Haycroft, Ebene R 1 ; Wen Shi Lee 2 ; Wheatley, Adam K 1 ; Juno, Jennifer A 1   VIAFID ORCID Logo  ; Adair, Amy 3 ; Pymm, Phillip 3 ; Redmond, Samuel J 1 ; Gherardin, Nicholas A 1   VIAFID ORCID Logo  ; Godfrey, Dale I 1 ; Wai‐Hong Tham 3 ; Kent, Stephen J 4   VIAFID ORCID Logo  ; Chung, Amy W 1   VIAFID ORCID Logo 

 Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia 
 Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia 
 The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia 
 Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia; Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia 
Section
Original Articles
Publication year
2022
Publication date
2022
Publisher
John Wiley & Sons, Inc.
e-ISSN
20500068
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2728832917
Copyright
© 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.